Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Summary

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor (CTGF). CTGF triggers the production of collagen and fibronectin, which cause scarring and thickening of the lungs. Participants will be assigned sequentially to one of the 3 dose group: Low, medium, and high FG-3019.

Timeline

Start

2003-12-08

Primary completion

—

Completion

2004-05

Drugs

Indications